mondoBIOTECH and Bachem have announced the conclusion of a longterm cooperation. In the frame of the agreement with Interferon Medical Use in Collina d’Oro, Switzerland – a 100% affiliate of mondoBIOTECH Holding – Bachem provides its comprehensive know-how on peptides and its longstanding experience in the manufacture of peptides and finished pharmaceutical products. Bachem will receive unlimited access to the comprehensive and further increasing number of development projects of mondoBIOTECH for the treatment of rare diseases. Bachem will be in charge of providing peptide-based active ingredients required by mondoBIOTECH, sterile finished products to be used in clinical trials
as well as the appropriate regulatory documents. Furthermore, Bachem is entitled to produce current developmental orphan drugs for mondoBIOTECH, once approved.
“As a global company located in Switzerland we very much look forward to the opportunity of
jointly manufacturing products ‘made in Switzerland’ with Bachem, the world leader in
peptides,” said Fabio Cavalli, CEO and chief business architect of mondoBIOTECH.
Walter Isler, head of marketing and sales at Bachem, commented: “The agreed
cooperation is another step in our longstanding successful collaboration with mondoBIOTECH
and offers Bachem additional market potential. On the basis of this agreement Bachem gets
access to a multitude of peptide projects and thereby also further broadens its competency in
the manufacture of sterile finished products. Bachem is pleased to be strategic partner of
mondoBIOTECH and to support the company in its fight against rare diseases.”
About rare diseases
Currently about 7,000 rare diseases are known.
Rare diseases are a heterogeneous group of diseases that manifest themselves in almost any
organ and may have a systemic expression. Frequently they are debilitating diseases that require
sophisticated treatment and care. They are a heavy burden for patients and their families and
partly lead to death during childhood or adolescence. According to the definition valid
in Europe, a disease is ‘rare’ when less than one out of 2,000 people suffers from a specific
clinical syndrome. However, together these diseases by no means are a rare phenomenon; in
the European Union about 27 to 36 million people are affected.